IPCALAB - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 4.0
| Stock Code | IPCALAB | Market Cap | 39,274 Cr. | Current Price | 1,550 ₹ | High / Low | 1,624 ₹ |
| Stock P/E | 39.1 | Book Value | 292 ₹ | Dividend Yield | 0.26 % | ROCE | 17.6 % |
| ROE | 12.6 % | Face Value | 1.00 ₹ | DMA 50 | 1,487 ₹ | DMA 200 | 1,433 ₹ |
| Chg in FII Hold | 0.20 % | Chg in DII Hold | 0.54 % | PAT Qtr | 303 Cr. | PAT Prev Qtr | 305 Cr. |
| RSI | 57.7 | MACD | 22.3 | Volume | 2,72,043 | Avg Vol 1Wk | 4,44,268 |
| Low price | 1,168 ₹ | High price | 1,624 ₹ | PEG Ratio | -53.6 | Debt to equity | 0.11 |
| 52w Index | 83.8 % | Qtr Profit Var | 13.4 % | EPS | 31.7 ₹ | Industry PE | 27.6 |
📊 Analysis: IPCALAB shows moderate intraday strength with RSI at 57.7 (neutral to slightly bullish) and MACD at 22.3 (positive crossover). Price is trading above both 50 DMA (1,487 ₹) and 200 DMA (1,433 ₹), indicating short-term bullish momentum. Volume is below average, which reduces conviction, but fundamentals remain solid (ROCE 17.6%, ROE 12.6%). The stock is near its 52-week high (1,624 ₹), so upside may be capped intraday.
💰 Optimal Buy Price: 1,540–1,550 ₹ (near support, above 1,487 ₹ DMA).
🎯 Profit Exit Levels: 1,580 ₹ (first resistance), 1,610 ₹ (second resistance).
🛡️ Stop-Loss: 1,525 ₹ (below intraday support).
📈 If Already Holding: Exit near 1,580–1,610 ₹ if momentum indicators show continuation with volume support. If price fails to sustain above 1,540 ₹, consider exiting to protect capital.
✅ Positive
- Strong ROCE (17.6%) and ROE (12.6%)
- Trading above 50 DMA and 200 DMA
- EPS at 31.7 ₹ supports earnings visibility
- FII holding increased (+0.20%)
- DII holding increased (+0.54%)
⚠️ Limitation
- Volume below average, reducing intraday conviction
- High P/E at 39.1 compared to industry PE of 27.6
- PEG ratio negative (-53.6), valuation concerns
📉 Company Negative News
- PAT slightly declined (303 Cr vs 305 Cr)
- High valuation relative to peers
📈 Company Positive News
- Quarterly profit variation at +13.4%
- Institutional interest rising (FII & DII holdings up)
- Dividend yield at 0.26% provides minor income support
🏭 Industry
- Industry PE at 27.6 vs IPCALAB PE at 39.1 (stock appears overvalued)
- Pharma sector showing strong 52-week index growth (83.8%)
🔎 Conclusion
IPCALAB is fundamentally strong with bullish technical signals, but valuation is stretched and volume is below average. Suitable for cautious intraday trades near support with strict stop-loss. Best for short scalps today, with potential upside if momentum sustains toward resistance levels.
Would you like me to extend this into a basket overlay with peers (Sun Pharma, Divi’s Lab, Dr. Reddy’s) so you can benchmark IPCALAB’s intraday setup against sector leaders for confirmation signals?